Article
A pancreatic cancer organoid platform identifies an inhibitor specific to mutant KRAS.
Cell stem cell - 4 Jan 2024
Duan Xiaohua, Zhang Tuo, Feng Lingling, de Silva Neranjan, Greenspun Benjamin, Wang Xing, Moyer Jenna, Martin M Laura, Chandwani Rohit, Elemento Olivier, Leach Steven D, Evans Todd, Chen Shuibing, Pan Fong Cheng
Abstract excerpt
KRAS mutations, mainly G12D and G12V, are found in more than 90% of pancreatic ductal adenocarcinoma (PDAC) cases. The success of drugs targeting KRASG12C suggests the potential for drugs specifically targeting these alternative PDAC-associated KRAS mutations. Here, we report a high-throughput drug-screening platform using a series of isogenic murine pancreatic organoids that are wild type (WT) or contain common...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.